SNAP-8
Also known as: Acetyl Octapeptide-3, Acetyl Octapeptide-1, Ac-EEMQRRNR-NH2, Leuphasyl, SNAP-25 octapeptide mimetic
Cosmeceutical signal peptide / SNARE-targeting neuropeptide mimetic
What it is
Skincare formulators and consumers looking for topical anti-wrinkle alternatives to botulinum toxin use SNAP-8 (Acetyl Octapeptide-3) in serums and creams. It is a synthetic eight-amino-acid peptide designed to compete with SNAP-25 at the SNARE complex, aiming to reduce the muscle contractions that deepen expression lines.
The scientific side
SNAP-8 is an eight-amino-acid acetylated peptide (Ac-EEMQRRNR-NH2) that is a longer analogue of the hexapeptide Argireline (Acetyl Hexapeptide-3, Ac-EEMQRR-NH2). Both peptides are patterned on the N-terminal sequence of SNAP-25 (synaptosomal-associated protein 25 kDa), one of the three core proteins of the SNARE (Soluble NSF Attachment protein REceptor) complex. The SNARE complex — comprising SNAP-25, syntaxin-1, and VAMP/synaptobrevin — drives calcium-dependent vesicular fusion and neurotransmitter release at the presynaptic terminal. By mimicking a segment of SNAP-25, SNAP-8 is proposed to compete with endogenous SNAP-25 for incorporation into the ternary SNARE complex, thereby interfering with complex assembly or stability and partially attenuating acetylcholine exocytosis at the neuromuscular junction. The original characterisation of the hexapeptide analogue (PMID 18498523) demonstrated that the peptide inhibited neurotransmitter release with a potency similar to botulinum neurotoxin type A but with far lower efficacy, and that the mechanism involved disruption of SNARE complex formation rather than proteolytic cleavage of SNAP-25 as seen with botulinum toxins. A later study (PMID 23562512) confirmed that a cell-permeable truncated form of SNAP-25 delivered topically could block presynaptic neurotransmitter transport by acting as a competitive inhibitor of SNARE complex formation and produce muscle paralysis comparable to botulinum toxin A in compound muscle action potential measurements. Research published in 2024 (PMID 38888508) extended this model by identifying that an abnormally elevated interaction between SNAP-25 and RAB3A proteins in the synaptic vesicle cycle contributes to wrinkle-associated reductions in dermal thickness, and that a peptide modulating this interaction could reduce periorbital and perinasal wrinkles topically. Unlike botulinum toxins, which irreversibly cleave SNARE proteins, SNAP-8's competitive inhibition is theoretically reversible and concentration-dependent, which may limit its depth of effect but also its systemic risk. Because SNAP-8 carries two additional amino acids compared with Argireline, it is marketed as having greater receptor affinity and potentially stronger or longer-lasting SNARE interference, though no head-to-head human clinical trial directly comparing SNAP-8 and Argireline efficacy has been identified in the retrieved literature.
Class: Cosmeceutical signal peptide / SNARE-targeting neuropeptide mimetic
Administration & storage
- Administration
- Subdermal injection of argireline (analogue) into rat flap model for mechanistic collagen studies (PMID 42675285) — not a cosmetic protocolFacial injection of argireline reported in one adverse-event case report (PMID 33748252) — M. abscessus infection at injection sites; no published clinical safety or efficacy data support injectable SNAP-8 use
- Storage
- General guidance for acetylated peptides: store lyophilised powder below 4°C, protected from light and moisture; aqueous solutions may be stored at 2–8°C with appropriate preservative system. No stability-specific PubMed data retrieved for SNAP-8 itself.
Legal & regulatory status
Not approved as a drug. Permitted as a cosmetic ingredient under FDA's general cosmetic framework; no IND or NDA on file for SNAP-8 specifically.
Not listed on the WADA Prohibited List. Not classified as a prohibited substance in sport as of 2026.
No drug identification number (DIN) or natural health product (NHP) licence. Permissible as a topical cosmetic ingredient when used in compliant cosmetic formulations.
What it's studied for
- Reduction of expression-line depth (periorbital, glabellar, perioral wrinkles) Tier 3 — Indirect (analogue RCT + mechanistic in vitro)
- Topical neuromodulation via SNARE complex interference Tier 2 — Mechanistic in vitro and ex vivo
- Skin collagen quality improvement in aged tissue Tier 3 — In vivo animal model
- Combination anti-aging cosmeceutical formulation (with retinol, bakuchiol, or botanical extracts) Tier 3 — Open-label clinical studies and in vivo zebrafish models
- Enhanced transdermal delivery via iontophoresis or microneedle devices Tier 2 — In vitro permeation and ex vivo skin studies
- Controlled-release facial lifting via PDO thread loading Tier 4 — Pilot laboratory and preliminary clinical report
- SNARE-target context: differentiating botulinum toxin type A versus type B mechanisms Tier 2 — Clinical pharmacology review
Safety signals
- Mycobacterium abscessus infection at injection site (argireline analogue, injectable off-label use)
- No primary skin irritation or oral toxicity at high doses (hexapeptide analogue, Argireline)
- No allergic reactions documented during acetyl hexapeptide-8 topical treatment (26 patients, skin disorders)
- Injectable argireline produced no detectable tissue-level effect on collagen composition in rat flap model (no biological activity confirmed at tested dose)
- Elevated Substance P expression with combination botulinum toxin A + argireline in rat model (neurogenic inflammatory signal)
- Risk of microbial contamination with non-sterile preparation when used in any injection context
- Poor passive skin penetration may limit topical efficacy at low concentrations (hydrophilicity and MW ~1000 Da)
- No human adverse events reported in topical RCT of analogue (Argireline, 60 subjects, 4 weeks)
All studies (9)
Frequently asked
Is SNAP-8 stronger than Argireline (Acetyl Hexapeptide-3)?
SNAP-8 and Argireline are closely related peptides: both are patterned on the N-terminal region of the SNAP-25 protein and both aim to interfere with the SNARE complex that drives neurotransmitter release. SNAP-8 has two additional amino acids (it is an octapeptide versus a hexapeptide). Manufacturer claims suggest greater affinity for the SNARE complex, but no independently published, peer-reviewed, head-to-head clinical trial comparing the two peptides has been identified in the PubMed literature. All published human clinical data used to support the SNAP-25 mimetic peptide class — including the 48.9% responder rate (PMID 23417317) and the 30% wrinkle depth reduction (PMID 18498523) — come from Argireline studies, not SNAP-8 studies.
Can SNAP-8 replace botulinum toxin injections?
No published evidence supports SNAP-8 as an equivalent replacement for botulinum toxin A injections. The analogue Argireline was shown in vitro to inhibit neurotransmitter release with potency similar to BoNT-A but much lower efficacy (PMID 18498523). Botulinum toxin A irreversibly cleaves SNAP-25 for weeks; topically applied SNAP-25 mimetics offer competitive, reversible, and concentration-dependent partial inhibition. A 2024 study found the SNAP-25/RAB3A axis relevant to wrinkle formation (PMID 38888508), but topical peptide effects are milder and shorter-lasting than neurotoxin injections. SNAP-8 is better characterised as a complementary ingredient for gradual maintenance than as a clinical substitute.
Is it safe to inject SNAP-8?
No safety or efficacy data from peer-reviewed clinical trials supports injectable use of SNAP-8 in cosmetic practice. A case report (PMID 33748252) documented a serious Mycobacterium abscessus infection in a patient who received facial injections of the closely related Argireline, requiring 5 months of combination antibiotics. Injectable use of cosmetic peptide solutions carries inherent infection risk when sterility cannot be guaranteed. Available published safety data covers topical application only.
How long does it take to see results with SNAP-8 topically?
Based on studies of the closely related analogue Argireline, the published time to measurable wrinkle improvement in clinical trials is 4–8 weeks with twice-daily topical application. Wang et al. (PMID 23417317) reported significant objective improvements after 4 weeks; the combination retinol-hexapeptide study (PMID 37538317) measured improvements at 4 and 8 weeks. No specific SNAP-8 clinical timeline data was identified in the retrieved literature.
Does SNAP-8 work better with iontophoresis or microneedles?
Research on the hexapeptide analogue (Argireline/AHP-3) suggests that active delivery methods substantially improve skin permeation: iontophoresis increased peptide permeation up to 30-fold through excised human skin (PMID 25786877), and 3D-printed personalised microneedle patches demonstrated enhanced in vitro transdermal delivery with good mechanical integrity and minimal cytotoxicity (PMIDs 33068646, 31952064). These findings support the rationale for using such technologies with SNAP-8, but no in-human clinical trial using SNAP-8 specifically with iontophoresis or microneedles has been identified in the retrieved literature.